Contrast Agent, Liquid Biopsy Tool Or Treatment? Earli Might Deliver All Three At Once

The company has developed a technology that uses engineered DNA to reprogram cancer cells, forcing them to produce substances that could be used to help image, detect or even destroy them.

San Francisco-based Earli is joining the liquid biopsy space with technology that uses cancer’s properties against itself. 

Since being founded in 2018, the company has raised nearly $60m to develop its technology which, if successful, could be...

More from Oncology

More from Device Area

Endo Tools, Fujifilm Partner to Fast-Track Endomina Rollout Across MEA Region

 
• By 

CEO Alexandre Chau told Medtech Insight that the Middle East and Africa presented the ideal mix of market potential, physician training opportunities, and regulatory readiness when the company was considering expansion markets beyond Europe and the US.

From Imitation To Action: Johns Hopkins Robot Autonomously Performs Key Step In Gallbladder Surgery

 
• By 

Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.